WINTON GROUP Ltd Trims Position in Thermo Fisher Scientific Inc. (TMO)
WINTON GROUP Ltd cut its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 33.9% in the 4th quarter, Holdings Channel reports. The firm owned 66,958 shares of the medical research company’s stock after selling 34,350 shares during the period. WINTON GROUP Ltd’s holdings in Thermo Fisher Scientific were worth $12,714,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of TMO. Capital Research Global Investors raised its holdings in shares of Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after acquiring an additional 3,973,136 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Thermo Fisher Scientific by 2,058.1% in the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after acquiring an additional 2,233,522 shares during the last quarter. Veritas Asset Management LLP raised its holdings in shares of Thermo Fisher Scientific by 44.1% in the third quarter. Veritas Asset Management LLP now owns 3,503,259 shares of the medical research company’s stock worth $662,817,000 after acquiring an additional 1,072,500 shares during the last quarter. Meritage Group LP acquired a new position in shares of Thermo Fisher Scientific in the third quarter worth $201,383,000. Finally, Capital World Investors raised its holdings in shares of Thermo Fisher Scientific by 6.1% in the second quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after acquiring an additional 671,637 shares during the last quarter. 86.54% of the stock is owned by hedge funds and other institutional investors.
In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $209.26, for a total transaction of $1,046,300.00. Following the completion of the sale, the chief financial officer now owns 30,741 shares of the company’s stock, valued at $6,432,861.66. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William G. Parrett sold 1,000 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $209.80, for a total value of $209,800.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 96,327 shares of company stock valued at $19,681,772. 0.49% of the stock is owned by company insiders.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. The firm had revenue of $6.05 billion during the quarter, compared to analyst estimates of $5.72 billion. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The business’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.41 earnings per share. equities analysts predict that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date of this dividend is Wednesday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s payout ratio is 10.71%.
TMO has been the subject of a number of analyst reports. ValuEngine raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. BTIG Research initiated coverage on Thermo Fisher Scientific in a report on Friday, January 5th. They issued a “buy” rating and a $230.00 price target for the company. Bank of America boosted their price target on Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, February 1st. Zacks Investment Research raised Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Finally, Evercore ISI initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 target price for the company. Two investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $220.50.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.